open access
Association between cardiovascular disease, cardiovascular drug therapy, and in-hospital outcomes in patients with COVID-19: data from a large single-center registry in Poland
Affiliations- Department of Cardiology, Interventional Electrocardiology and Arterial Hypertension, Jagiellonian University Medical College, Kraków, Poland
- Department of Internal Diseases and Geriatrics, Jagiellonian University Medical College, Kraków, Poland
- Department of Metabolic Diseases and Diabetology, Jagiellonian University Medical College, Kraków, Poland
- Department of Infectious and Tropical Diseases, Jagiellonian University Medical College, Kraków, Poland
- Department of Pulmonology and Allergology, Jagiellonian University Medical College, Kraków, Poland
- Department of General, Oncological, Metabolic, and Emergency Surgery, Jagiellonian University Medical College, Kraków, Poland
- Department of Interdisciplinary Intensive Care, Jagiellonian University Medical College, Kraków, Poland
- Department of Neurology, Jagiellonian University Medical College, Kraków, Poland
- Department of Gastroenterology and Hepatology, Jagiellonian University Medical College, Kraków, Poland
- Department of Nephrology and Dialysis, Jagiellonian University Medical College, Kraków, Poland
- Department of Otolaryngology, Jagiellonian University Medical College, Kraków, Poland
- Department of Urology and Oncological Urology, Jagiellonian University Medical College, Kraków, Poland
- Department of Toxicology, Jagiellonian University Medical College, Kraków, Poland
- Department of Rheumatology and Immunology, Jagiellonian University Medical College, Kraków, Poland
- Department of Diagnostic Imaging Unit, Jagiellonian University Medical College, Kraków, Poland
- Department of Psychiatry for Adults, Children, and Youth, Jagiellonian University Medical College, Kraków, Poland
- Department of Trauma and Orthopedics, Jagiellonian University Medical College, Kraków, Poland
open access
Abstract
Background: The coronavirus disease 19 (COVID-19) recently became one of the leading causes of death worldwide, similar to cardiovascular disease (CVD). Coexisting CVD may influence the prognosis of patients with COVID-19.
Aims: We analyzed the impact of CVD and the use of cardiovascular drugs on the in-hospital course and mortality of patients with COVID-19.
Methods: We retrospectively studied data for consecutive patients admitted to our hospital, with COVID-19 between March 6th and October 15th, 2020.
Results: 1729 patients (median interquartile range age 63 [50–75] years; women 48.8%) were included. Overall, in-hospital mortality was 12.9%. The most prevalent CVD was arterial hypertension (56.1%), followed by hyperlipidemia (27.4%), diabetes mellitus (DM) (25.7%), coronary artery disease (16.8%), heart failure (HF) (10.3%), atrial fibrillation (13.5%), and stroke (8%). Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEIs/ARBs) were used in 25.0% of patients, β-blockers in 40.7%, statins in 15.6%, and antiplatelet therapy in 19.9%. Age over 65 years (odds ratio [OR], 6.4; 95% CI, 4.3–9.6), male sex (OR, 1.4; 95% CI, 1.1–2.0), pre-existing DM (OR, 1.5; 95% CI, 1.1–2.1), and HF (OR, 2.3; 95% CI, 1.5–3.5) were independent predictors of in-hospital death, whereas treatment with ACEIs/ARBs (OR, 0.4; 95% CI, 0.3–0.6), β-blockers (OR, 0.6; 95% CI, 0.4–0.9), statins (OR, 0.5; 95% CI, 0.3–0.8), or antiplatelet therapy (OR, 0.6; 95% CI: 0.4–0.9) was associated with lower risk of death.
Conclusions: Among cardiovascular risk factors and diseases, HF and DM appeared to increase in-hospital COVID-19 mortality, whereas the use of cardiovascular drugs was associated with lower mortality.
Abstract
Background: The coronavirus disease 19 (COVID-19) recently became one of the leading causes of death worldwide, similar to cardiovascular disease (CVD). Coexisting CVD may influence the prognosis of patients with COVID-19.
Aims: We analyzed the impact of CVD and the use of cardiovascular drugs on the in-hospital course and mortality of patients with COVID-19.
Methods: We retrospectively studied data for consecutive patients admitted to our hospital, with COVID-19 between March 6th and October 15th, 2020.
Results: 1729 patients (median interquartile range age 63 [50–75] years; women 48.8%) were included. Overall, in-hospital mortality was 12.9%. The most prevalent CVD was arterial hypertension (56.1%), followed by hyperlipidemia (27.4%), diabetes mellitus (DM) (25.7%), coronary artery disease (16.8%), heart failure (HF) (10.3%), atrial fibrillation (13.5%), and stroke (8%). Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEIs/ARBs) were used in 25.0% of patients, β-blockers in 40.7%, statins in 15.6%, and antiplatelet therapy in 19.9%. Age over 65 years (odds ratio [OR], 6.4; 95% CI, 4.3–9.6), male sex (OR, 1.4; 95% CI, 1.1–2.0), pre-existing DM (OR, 1.5; 95% CI, 1.1–2.1), and HF (OR, 2.3; 95% CI, 1.5–3.5) were independent predictors of in-hospital death, whereas treatment with ACEIs/ARBs (OR, 0.4; 95% CI, 0.3–0.6), β-blockers (OR, 0.6; 95% CI, 0.4–0.9), statins (OR, 0.5; 95% CI, 0.3–0.8), or antiplatelet therapy (OR, 0.6; 95% CI: 0.4–0.9) was associated with lower risk of death.
Conclusions: Among cardiovascular risk factors and diseases, HF and DM appeared to increase in-hospital COVID-19 mortality, whereas the use of cardiovascular drugs was associated with lower mortality.
Keywords
COVID-19, cardiovascular disease, cardiovascular drugs, in-hospital mortality
About this articleTitle
Association between cardiovascular disease, cardiovascular drug therapy, and in-hospital outcomes in patients with COVID-19: data from a large single-center registry in Poland
Journal
Kardiologia Polska (Polish Heart Journal)
Issue
Article type
Original article
Pages
773-780
Published online
2021-04-29
Page views
1613
Article views/downloads
1379
DOI
10.33963/KP.15990
Pubmed
Bibliographic record
Kardiol Pol 2021;79(7-8):773-780.
Keywords
COVID-19
cardiovascular disease
cardiovascular drugs
in-hospital mortality
Authors
Michał Terlecki
Wiktoria Wojciechowska
Marek Klocek
Agnieszka Olszanecka
Katarzyna Stolarz-Skrzypek
Tomasz Grodzicki
Maciej Małecki
Barbara Katra
Aleksander Garlicki
Monika Bociąga-Jasik
Krzysztof Sładek
Andrzej Matyja
Jerzy Wordliczek
Agnieszka Słowik
Tomasz Mach
Katarzyna Krzanowska
Marcin Krzanowski
Paweł Stręk
Piotr Chłosta
Piotr Hydzik
Mariusz Korkosz
Tadeusz Popiela
Maciej Pilecki
Artur Gądek
Marek Rajzer
